贝达喹啉、利奈唑胺和普雷托马尼（BPaL）在多药耐药（MDR）结核感染家庭聚集性病例中的首次使用。

{"title":"贝达喹啉、利奈唑胺和普雷托马尼（BPaL）在多药耐药（MDR）结核感染家庭聚集性病例中的首次使用。","authors":"Marcus Pratt, Mark McNicol, Michael Hunter, Martin Dedicoat","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":94250,"journal":{"name":"The Ulster medical journal","volume":"93 2","pages":"55-57"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633317/pdf/","citationCount":"0","resultStr":"{\"title\":\"First use of Bedaquiline, Linezolid, and Pretomanid (BPaL) in a family cluster of multi-drug resistant (MDR) TB infection.\",\"authors\":\"Marcus Pratt, Mark McNicol, Michael Hunter, Martin Dedicoat\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":94250,\"journal\":{\"name\":\"The Ulster medical journal\",\"volume\":\"93 2\",\"pages\":\"55-57\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633317/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Ulster medical journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Ulster medical journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}